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Abstract: To examine the effect of exponential, Weibull and Gompertz distributions on 
sample size determination for superiority trials (STs) or non-inferiority trials (NTs) with 
time-to-event data, we present two sample size formulas for STs or NTs based on 
Weibull and Gompertz distributions, respectively. The formulas are compared with the 
current exponential formula to examine their performance. The simulation results show 
that the sample size formula based on the Weibull distribution is the most robust among 
the three formulas in STs or NTs. We suggest that recognizing the appropriate 
distribution in advance is beneficial for proper project planning and that assuming a 
Weibull distributed survival time is most advantageous in STs or NTs. 
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 1. Introduction 
A time-to-event endpoint is used as the primary endpoint in many studies such as 
those on oncology and cardiovascular disease. In the planning stage of a clinical trial 
employing this type of endpoint, determining an adequate sample size is one of the most 
fundamental steps. An appropriate sample size provides reasonable power to detect a 
clinically meaningful difference between treatment groups. Currently, sample size 
calculations usually assume that the failure time is exponentially distributed. Consider 
Quon’s study [1], which examined whether the addition of weekly cisplatin to daily 
radiation therapy (RT) would improve survival in patients with unresectable squamous 
cell head-and-neck carcinoma. The formula based on the exponential distribution may 
have been used for the sample size calculation. However, the shape of the Kaplan-Meier 
curves was not consistent with the assumption that the event times are exponentially 
distributed, as was shown in Figure 2 in the original paper [1]. The hazard rates of both 
arms decreased along with the survival time. This issue may also arise in a clinical study 
incorporating a non-inferiority hypothesis. In other words, incorrect assumptions about 
the distribution of event times may result in an undesired sample size and power 
whether the study design uses superiority trials (STs) or non-inferiority trials (NTs). 
A few derivations of sample size formulas for time-to-event data have been 
published that were based on distributions other than exponential [2-5]. Heo et al [2], 
for instance, derived a sample size formula that compared two groups of Weibull 
distributed survival times based on Schoenfeld and Richter [6]. Gope [3] proposed a 
sample size calculation method for comparing fatigue time following a Weibull 
distribution in technology studies. In addition, a simulation based method for 
calculating sample sizes for group sequential trials under a Weibull distribution was 
proposed by Jiang et al [4]. Lu et al [5] derived sample size formulas for a Weibull 
model in order to design a two-stage seamless adaptive trial under different hypotheses. 
In 2015, Wu [7] derived three sample size formulas based on a Weibull distribution and 
some researchers’ work[6,8-10], for a randomized phase III clinical trial with general 
 entry distribution. one of the claims made in this paper is that the Weibull distribution is 
superior to the exponential distribution because of the inclusion of an additional 
parameter. Heo’s formula[2] is the same as Wu’s first formula without the loss to 
follow-up, and Rubinstein’s formula[11] was the same as Wu’s first formula under the 
circumstances with the uniform entry, exponential survival distribution and loss to 
follow-up. All these articles under STs aimed at demonstrating the performance of the 
presented formula under different distributions, where no one discussed the discrepancy 
when the wrong distributions are hypothesized. 
With respect to STs, Schoenfeld [8], Freedman [12], and Rubinstein’s [11] 
formulas are frequently used, where Rubinstein’s formula[11] has been used more 
frequently than the other two because of its consideration of accrual rate and censoring. 
Hence, the derived sample size formula with Weibull and Gompertz distribution for STs 
is planned to be based on Rubinstein’s research. 
In terms of sample size determination in NTs, some recently published methods 
assumed an exponential distribution [13-17]. In Rothmann’s work [13], the focus was to 
examine issues involving retention of a pre-specified fraction of the control effect. 
Some design considerations were also mentioned in the paper, such as the formulation 
of the hypotheses, the statistical methodology and the interpretations of an active 
control non-inferiority trial. Sample size formulas for NTs as discussed by Chow et al. 
[15] and Crisp and Curtis [16], which extended the work of Lachin and Foulkes [18] 
from superiority hypothesis testing to non-inferiority, have been adopted in software 
packages such as nQuery 7.0, PASS 12.0, etc. The formula’s power is biased in an 
unbalanced design study, and the bias increases as the two arms become more 
unbalanced or as the projected non-inferiority margin becomes farther from 1 [14]. 
Hence, Jung et al. [14] proposed a more accurate formula based on a non-inferiority 
log-rank test [15]. Subsequently, Jung and Chow [17] derived a generalized log-rank 
test and its sample size formula, which is more flexible (any survival distributions for 
two arms and any accrual pattern) and applicable for both superiority and 
 non-inferiority inference. This sample size formula is identical to that of the log-rank 
test by Schoenfeld [8] (if the hazard ratio is set to 1 under the null hypothesis) and is 
also identical to that of Jung [14] (if the hazard ratio is 1 under the alternative 
hypothesis).  
Commercially available software packages, including PASS, nQuery and EAST, 
can carry out the sample size based on the exponential distribution as well as a 
proportional hazard model. The same is true for standard textbooks [15,19], where 
sample size calculations under a Weibull model are not usually considered [7]. Because 
of the importance of the sample size, it is important to choose not only the methods of 
estimation but also the assumed distributions with caution. Although an exponential 
distribution may provide a reasonable approximation to the distribution of survival 
times over relatively short intervals, it typically does not adequately characterize the 
overall distribution of survival times because of its property of constant hazard over 
time [2]. Therefore, the Weibull and Gompertz distributions are considered in this paper. 
Two families of formulas based on the studies from Rubinstein [11] and Crisp and 
Curtis [16] are presented, and the robustness of three distributions in various situations 
are simulated. 
The sample size formulas based on the three distributions and two hypotheses are 
shown in the next section. The setting and results of simulations are described in the 
Simulations and Results sections. The section entitled Examples gives two real clinical 
trials as examples. We then summarize our conclusions in the final section. 
2. Methods 
Consider a study with two treatment groups, one control ( ) and one 
experimental ( ). The effect size of the study when incorporating a time-to-event 
endpoint is expressed as a hazard ratio, which is defined as , where 
 and  are the hazard rates in the control and experimental group, 
respectively. If  is constant, the proportional hazard assumption is satisfied.  
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 and  indicate the sample size of the control and experimental groups, respectively. 
Thus, the total sample size is . Only the balanced design is considered here, 
i.e., . The durations of enrollment and follow-up are denoted by  and , 
respectively, and the number of enrolled participants is assumed to have a Poisson 
distribution with parameter . Suppose that our primary endpoint is the time to an 
undesirable event, such as death, progression of cancer, etc. So, the higher the hazard 
rate is, the worse the efficacy is. 
Formulas for STs 
The hypotheses in the STs are usually set as  versus . The 
general form of the sample size formula from Rubinstein [11] is expressed as 
,    (1) 
where ( ) is the hazard ratio under , and  denotes the  quantile 
of the standard normal distribution. This is the first sample size formula to consider the 
enrollment period and accrual rate, which is reflected in the expression of  and . 
When the assumed survival distribution is exponential, i.e., the hazard function
, the expression for  is written as  
             ,                  (2) 
where  is the only parameter involved in the distribution of survival time, and  
denotes the hazard rate of identical exponential censoring distributions in both groups.  
If a Weibull distribution is assumed to be used for describing the survival time 
where the hazard function is ,  is expressed as  
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where  is the scale parameter of the Weibull distribution in group .  is 
the shape parameter of the Weibull distribution and is assumed to be identical in the two 
groups. Hence, the hazard ratio  is a constant.  
When the distribution of survival times is assumed to be Gompertz, i.e., the hazard 
function , the  in (1) is replaced by  
 ,     (4) 
where .  and  are the 
shape parameter and scale parameter, respectively. The shape parameter is again 
assumed to be identical across the two groups in order to ensure that the proportional 
hazard assumption is met. 
Formulas for NTs 
In NTs, the non-inferiority margin of the hazard ratio ( 0 ) is one of the most 
important pre-specified values. If the observed hazard ratio exceeds 0 , we declare the 
experimental group to be inferior to the control group; otherwise, the experimental 
group is non-inferior to the control group. So, given 0  in NTs, we intend to test 
0 0:H     against 01 :H    . The hazard ratio under  is indicated by 1
( 01   ). Under , the efficacy of the experimental group is identical to (or possibly 
better than) that of the control group ( 1 1  ) or slightly worse than that of the control 
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 group but within acceptable limits ( 1 01    ). To calculate the sample size, the 
general form of Crisp and Curtis’s formula [16] for NTs is: 
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The expression for xE  in NTs for the exponential (Formula (2)), Weibull (Formula (3)) 
and Gompertz (Formula (4)) survival distributions is the same as that for the STs. 
Determination of study duration 
It is difficult to directly derive the formula for study duration fT , thus, we 
recommend using the numerical calculation (e.g. Newton-Raphson method) to solve  
 ) 0setting fN N T （                              (6) 
for fT , where the settingN  is the pre-setting targeted number to enroll, The ( )fN T  is 
the function (1) or (5) of fT  as the unknown parameter. To make (6) have a solution, 
settingN  must satisfy  
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under NTs. 
Type of enrollment distribution 
In the aforementioned formulas, the enrollment distribution is assumed to be uniform 
over interval [0, R], where the accrual rate is constant, and the number enrolled 
participants has a Poisson distribution. The distribution with a decreasing accrual rate 
presented in Lachin and Foulkes’ study [18] is the truncated exponential distribution. It 
 provides a great deal of flexibility in describing the accrual rates over a fixed period 
[20]. Any density function of the accrual distribution can be employed by replacing the 
 in the integral in . See Maki’s paper [20] for other types of accrual distributions, 
such as increasing then constant, constant then decreasing, etc. 
3. Simulations 
Monte Carlo simulation studies were undertaken to verify the performance of 
sample size formulas when the survival time conformed to exponential, Weibull or 
Gompertz distributions in STs and NTs, respectively. While the simulations for STs and 
NTs use different sample size formulas and parameter settings, the generating processes 
for failure time and status are the same. 
The independently observed event times  are generated for the control and 
experimental groups under the assumed event rates, the hazard ratio ( ) and the 
censoring rate. For each subject, an enrollment time  is generated from the uniform 
distribution over , and a censoring time is generated from the exponential 
distribution with parameter . As mentioned above, the subjects are treated as censored 
if the time-to-event is not the minimum of the time-to-event, censoring time or closure 
time minus enrollment time. Thus, the final observed time is . 
Let  indicate that the event either occurs ( ) or is censored ( ). 
Then, 10000 independent trials were simulated for each sample size formula under 
each combination of parameters. Let type I error ( ) and power（ ） be 0.05 and 
0.80, respectively. Different values for  and  are selected for satisfying Weibull 
and Gompertz simulations. When the survival time was Weibull distributed, the 
decreasing (k={0.5, 0.7}), constant (k=1.0) and increasing (k={1.2, 1.5}) hazard rates 
were considered, and the incidence intensity of the control group was set to low, 
intermediate or high ( 0 {0.1,0.3,0.5,1.0,1.2}  ). In the simulations in which the failure 
time distribution was Gompertz, the shape and scale parameters were set to 
{0.5,0.7,1.0,1.2,1.5}G   and 0 {0.1 0.3,0.5,1.0,1.2}  ， , respectively. Random 
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 censoring absent ( ) and present ( ) were also considered. The parameters 
used in the sample size formulas were estimated using the averaged coefficients of 
parametric regression model of corresponding distribution, which was fitted to 20 trials 
of 50 subjects’ failure time generated by the real survival distribution with preseted 
parameters. Only the balanced design is considered in this section, i.e. 0 1 / 2N N N   
Additionally, the detail simulating process is illustrated. Firstly, 20 trials of 50 
subjects with a preset survival distribution, say Weibull, were generated. Then, 
exponential, Weibull and Gompertz regression models were fitted, and the averaged 
regressed coefficients were used for calculating the parameters utilized in each sample 
size formula. After the calculation of 3 sample sizes under this circumstance, 10000 
samples within each sample size group were taken from the preset distribution. As a 
result, the empirical powers of each sample size formula in each parameter combination 
of Weibull situation can be observed. 
For STs, the rejection of  by a two-sided Wald test of a Cox 
proportional hazards regression model yields the conclusion that the hazard rates of the 
two groups are not equal. The true hazard ratio 1
1 1,
1.2 1.5
       is then used to 
determine the sample size. For NTs, the non-inferiority margin 0  was 1.2 and 1.5 
while the true hazard ratio 1 was 1 to imply the same efficacy for the two groups. If 
the upper limit of the two-tailed 95% confidence interval (for the hazard ratio from a 
Cox proportional hazards regression model) is less than the non-inferiority margin, then 
non-inferiority is concluded. 
The parameter combinations for the Weibull and Gompertz failure time 
distributions are shown in Tables 1 and 2, respectively. The statistical package R 2.15.2 
was used to perform simulations under different survival distributions and to generate 
tables and graphs.  
4. Results 
In situations having the same  between STs and NTs, the required 
events are equal if  is identical, while the final sample size differs 
0  0.2 
0 0: 1H  
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 because of different hypotheses (different hazard rate in the experimental group). 
However, the key conclusion is analogous.  
The simulations and results for estimated study duration are similar as for the 
sample size since the formula of study duration is resulted from the sample size formula 
directly. The larger sample size needed with different survival distribution, and the 
larger study duration calculated. If the sample size is overestimated, the study duration 
is overestimated as well, and vice versa.  
Results of Superiority Trials  
The empirical power function assuming Weibull survival time in STs is shown in 
Figure 1 and Table A1. When the survival time has a Weibull distribution, the power 
using the Weibull formula is very close to the specified power, which is to be expected.  
The powers of both the exponential formula and Gompertz formula are heavily 
influenced by the shape parameter and censoring rate. In cases where the Weibull 
distribution has a decreasing hazard function with survival time ( ) (Figure 1-A, 
1-B, 1-F, 1-G), the empirical power of the exponential and Gompertz formula decreases 
from 1.0 to around 0.8 with increasing  and decreasing censoring. The sample size 
from exponential is larger than that from the Gompertz. When , the exponential 
formula is identical to the Weibull formula (Figure 1-C,1-H). The power of Gompertz 
formula is around 0.8 as well. When k is larger than 1.0 with random censoring (Figure 
1-D, 1-E, 1-I, 1-J), the power of the both formulas are a little lower than 0.8 with high 
censoring rate, and approaching 0.8 with an increasing  and a decreasing censoring 
rate. 
The results from simulation of the Gompertz survival time (Figure 2) show that the 
power calculated using the Weibull and exponential formula are not smaller than that of 
the Gompertz in presence of high censoring rate. The largest difference between 
Weibull and Gompertz is 0.225 when the censoring rate reaches 63.2% where the 
largest difference between exponential and Gompertz is 0.420. Along with the 
censoring rate decreasing, the power lines of exponential and Weibull cross the power 
line of Gompertz. The power of the other formula are larger than 0.8. But Weibull 
formula is closer to the Gompertz formula than exponential formula, where the power’s 
1k 
0
1k 
0
 differences between Weibull and Gompertz are less than 0.04. The details are listed in 
Table A2. 
Results of non-inferiority trials 
The empirical power functions using Weibull survival time in NTs are shown in 
Figure 3, and the details are listed in Table A3. 
The trends for the Gompertz distribution in the NTs are almost the same as those 
for STs. Power increases from approximately 0.6 to over 0.9 along with increasing , 
and the distances between the Gompertz and Weibull lines increase as the censoring rate 
increases. However, the trends for the exponential formula in the NTs differ from those 
in STs. 
For  (Figures 3-A, 3-B) with random censoring ( ), the exponential 
formula may overestimate the sample size; in addition, the largest empirical power for 
the exponential distribution is greater than 0.95, substantially larger than the 
pre-specified 0.80. So, using the exponential formula in this scenario may yield an 
unnecessarily large sample. In the case of k=1 (Figure 3-C), the formulas under the 
exponential and Weibull distributions are identical, and power is approximately 0.8. 
When  (Figure 3-D, 3-E), the exponential formula is closer to the necessary 
sample size with an increasing hazard function of survival time. 
In Figure 4, the results are similar to those from STs. The Weibull formula 
approaches the Gompertz formula. The details are listed in Table A4. 
Overall, when the survival time is Weibull distributed, sample sizes from the 
exponential and Gompertz formulas do not estimate the necessary sample size correctly. 
When the survival time is Gompertz distributed, the exponential sample size formula 
may underestimate the sample size needed, whereas the Weibull sample size formula is 
closer to the Gompertz formula and provides a reasonable estimation of the required 
sample size. 
5. Examples 
Example 1: Superiority clinical trial 
The sample size formula for STs is demonstrated using a phase III study of 
radiation therapy with ( ) or without ( ) cis-platinum in patients with 
0
1k  0.2 
1k 
1x  0x 
 unresectable squamous or undifferentiated carcinoma of the head and neck [1]. The 
major endpoint is failure-free survival measured from the date of randomization to the 
first evidence of progression, relapse or death. Because the Weibull formula has been 
shown to be more robust than the others, only the Weibull distribution sample size is 
illustrated in this example. 
In this study, 300 patients (150 patients in each arm) were needed to detect a 50% 
increase in the median survival between the two arms with 80% power and an overall 
Type I error of 0.05 by a two-sided test. So, the hazard ratio under  was assumed to 
be 1/1.5=0.667. An accrual rate of 75 patients/year was expected and therefore the 
participants were enrolled in 48 months (300/75*12). The maximum follow up time was 
13 years from the survival plots illustrated (Fig 2-3 in the original paper). 
The relationship between the median survival time and the Weibull hazard rate is
. While the expected 
median survival of 13 months in the control arm (the researchers decide in the original 
paper), the exponential rates are  and are  in the 
case of . The calculated sample sizes for several situations are shown in Table 3.  
When the survival distribution is exponential, the sample size needed per group is 
104 if there is no censoring and 193 if there is exponentially distributed censoring with 
a parameter of 0.05, which needs almost 90 patients larger than the case of no censoring. 
The calculated result of  is very close to that for  since the increment 
caused by the short research period is close to 0. 
Example 2: Non-inferiority clinical trial 
The sample size considerations for NTs are illustrated by a randomized, open-label, 
phase III, parallel clinical study [21]. The sample size was conducted to compare the 
efficacy on the patients with gastric cancer of Capecitabine/cisplatin (XP, experimental 
arm ) versus 5-fluorouracil/cisplatin (FP, standard/control arm, ). The 
primary outcome of the trial was progression-free survival (PFS), measured as time 
from randomization to the first date of documented disease progression or death. A total 
of 316 patients were randomized 1:1 to receive the XP and FP. 
The primary analysis of PFS was of the non-inferiority of XP to FP, as measured 
by the hazard ratio  with a non-inferiority margin of 1.40.  was rejected if 
1H
ln(survival rate)/( th power of survival time at the rate)k  
1
0 ln(0.5) /13 0.053    1 0.080 
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1.0k  1.5k 
1x  0x 
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 the upper limit of the 95% two-tailed confidence interval of the hazard ratio calculated 
using the Cox proportional hazards model was less than the non-inferiority margin. 
The median PFS was 5.6 months and 5.0 months for XP and FP, respectively. The 
exponential hazard rate can be derived as . The accrual interval was 22 
months, and the maximum follow-up time was approximately 24 months according to 
their survival plots. Because there is no description of the censoring, it appears in the 
paper’s figures that there was no random censoring in the perprotocol population.  
The parameter combinations with random censoring and without random censoring 
are considered. Under an exponential assumption, 141 patients and 190 patients are 
required without and with random censoring, respectively. In the case of decreasing 
hazard rates (i.e., ), the sample size that is needed is larger than that of the 
constant hazard rate because of the low incidence rate. If the hazard rate is increasing, 
the event incidence rate is slightly higher so that the numbers of required subjects 
decrease to 140 and 183. 
6. Conclusions 
In this paper, we presented two families of sample size formulas for exponential, 
Weibull and Gompertz distributions in superiority trials and non-inferiority clinical 
trials. A substantial number of simulations were conducted to investigate the robustness 
of these formulas. Unbalanced designs and disproportional hazards must be worked out 
in future studies.  
As shown in this paper, some situations may result in a waste of resources or in an 
underestimation of the sample size. The Weibull sample size formula worked relatively 
well in the simulated scenarios, in which the proportional hazard assumption held. 
Therefore, we suggest that recognizing the appropriate distribution in advance is very 
helpful for planning the project appropriately, and it is better to assume a Weibull 
distributed survival time in superiority trials or non-inferiority clinical trials unless there 
is clear evidence that the survival time has some other distribution. 
 
  
0 0.139 
0.5k 
 Acknowledgments 
This work was supported by the National Natural Science Foundation of China 
(81673268) and the Natural Science Foundation of Guangdong Province, China 
(2017A030313812). 
 
References: 
1. Quon H and Leong T, et al. Phase III study of radiation therapy with or without 
cis-platinum in patients with unresectable squamous or undifferentiated carcinoma 
of the head and neck: an intergroup trial of the Eastern Cooperative Oncology 
Group (E2382). International Journal of Radiation Oncology* Biology* Physics. 
2011; 81 (3): 719-725. 
2. Heo M and Faith MS et al. Power and sample size for survival analysis under the 
Weibull distribution when the whole lifespan is of interest." Mechanisms of ageing 
and development. 1998; 102 (1): 45--53. 
3. Gope PC. Determination of sample size for estimation of fatigue life by using 
Weibull or log-normal distribution. International Journal of Fatigue. 1999; 21 (8): 
745--752. 
4. Jiang Z, Wang L, Xia J et al. A Practical Simulation Method to Calculate Sample 
Size of Group Sequential Trials for Time-to-Event Data under Exponential and 
Weibull Distribution. PloS one. 2012; 7 (9): e44013. 
5. Lu Q and Tse SK et al. Analysis of time-to-event data with nonuniform patient entry 
and loss to follow-up under a two-stage seamless adaptive design with weibull 
distribution. J Biopharm Stat. 2012; 22 (4): 773-84. 
 6. Schoenfeld DA and Richter JR. Nomograms for calculating the number of patients 
needed for a clinical trial with survival as an endpoint. Biometrics. 1982; 163-170. 
7. Wu J. Power and Sample Size for Randomized Phase III Survival Trials under the 
Weibull Model. Journal of Biopharmaceutical Statistics. 2015; 25(1):16-28. 
8. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. 
Biometrics. 1983; 39 (2): 499-503. 
9. Sprott DA. Normal likelihoods and their relation to large sample theory of 
estimation. Biometrika. 1973; 60 (3): 457-465. 
10. Cox DR and Oakes D. Analysis of survival data, CRC Press, 1984. 
11. Rubinstein LV and Gail MH et al. Planning the duration of a comparative clinical 
trial with loss to follow-up and a period of continued observation. Journal of chronic 
diseases. 1981; 34 (9): 469-479. 
12. Freedman LS. Tables of the number of patients required in clinical trials using the 
logrank test. Statistics in Medicine. 2006; 1 (2): 121--129. 
13. Rothmann M and Li N et al. Design and analysis of non-inferiority mortality trials 
in oncology. Statistics in Medicine. 2003; 22 (2): 239-264. 
14. Jung S and Kang SJ et al. Sample size computation for two-sample noninferiority 
log-rank test. Journal of Biopharmaceutical Statistics. 2005; 15 (6): 969--979. 
15. Chow S, Wang H and Shao J. Sample size calculations in clinical research. Boca 
Raton, Chapman & Hall/CRC, 2008. 
16. Crisp A and Curtis P. Sample size estimation for non-inferiority trials of 
time-to-event data. Pharmaceutical Statistics. 2008; 7 (4): 236--244. 
 17. Jung SH and Chow SC. On Sample Size Calculation for Comparing Survival Curves 
Under General Hypothesis Testing. Journal of Biopharmaceutical Statistics. 2012; 
22 (3): 485--495. 
18. Lachin JM and Foulkes MA. Evaluation of sample size and power for analyses of 
survival with allowance for nonuniform patient entry, losses to follow-up, 
noncompliance, and stratification. Biometrics. 1986; 507-519. 
19. Julious SA and Tan SB et al. Sample Size Calculations for Clinical Trials, John 
Wiley & Sons, Ltd: 37-53, 2010. 
20. Maki E. Power and sample size considerations in clinical trials with competing risk 
endpoints. Pharmaceutical Statistics. 2006; 5 (3): 159-171. 
21. Kang Y and Kang W et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as 
first-line therapy in patients with advanced gastric cancer: a randomised phase III 
noninferiority trial. Annals of oncology. 2009; 20 (4): 666-673. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1. The parameter set for simulating trials when failure time is Weibull distributed
Parameters Values for STs Values for NTs 
 0.5, 0.7, 1.0, 1.2, 1.5 0.5, 0.7, 1.0, 1.5, 2.0 
 0.1, 0.3, 0.5, 1.0, 1.2 0.5, 0.7, 0.8, 1.0, 2.0 
 0, 0.2 0, 0.2 
( fT , R ) (6,2) (12,2) 
( , ) or (
1 , 0 ) (1/1.2,1.0), (1/1.5,1.0) (1.0,1.2), (1.0,1.5) 
Notes:  
 
Table 2. The parameter set for simulating trials when failure time is Gompertz distributed
Parameters Values for STs Values for NTs 
 0.5, 0.7, 1.0, 1.2, 1.5 0.05, 0.1, 0.5, 1.0 
 0.1, 0.3, 0.5, 1.0, 1.2 0.05, 0.1, 0.5, 1.0 
 0, 0.2 0, 0.2 
( fT , R ) (2,1) (12,2) 
( , ) or (
1 , 0 ) (1/1.2,1.0), (1/1.5,1.0) (1.0,1.2), (1.0,1.5) 
Notes:  
 
Table 3. Sample sizes needed for different parameter combinations assumed in Example 1 
          N(per group) 
0.5  0.192  0.288  0.667 0 104
        0.05  193 
1.0  0.053  0.080  0.667  0  97 
      0.05 187
1.5  0.015  0.022  0.667  0  97 
        0.05  183 
Notes:  ,  T 156f  ,  48R  ,  , power=0.8; number of events=96 
 
Table 4. Sample sizes needed for different parameter combinations assumed in Example 2 
    0     N(per group) 
0.5  0.310  1.40  0 167
      0.05  218 
1.0  0.139  1.40  0  141 
      0.05 190
1.5  0.062  1.40  0  140 
      0.05  183 
Notes: 
1 1  ,  ,  22R  ,  , power=0.8; number of events=139 
k
0

1 0
1 1 0• ; 0.05; Power 0.8     
G
0

1 0
1 1 0• ; 0.05; Power 0.8     
k 0 1 1 
0 1  0.05 
k 0 
24fT  0.05 
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